Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
11 03 2021
Historique:
received: 14 05 2020
accepted: 04 09 2020
pubmed: 30 9 2020
medline: 27 7 2021
entrez: 29 9 2020
Statut: ppublish

Résumé

Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed "satellites," were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL.

Identifiants

pubmed: 32992344
pii: S0006-4971(21)00552-8
doi: 10.1182/blood.2020007039
pmc: PMC7976441
doi:

Substances chimiques

Immunoglobulin Heavy Chains 0
Immunoglobulin Variable Region 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1365-1376

Subventions

Organisme : NCI NIH HHS
ID : R01 CA238523
Pays : United States

Informations de copyright

© 2021 by The American Society of Hematology.

Références

Nature. 2012 Sep 13;489(7415):309-12
pubmed: 22885698
Leukemia. 2013 Nov;27(11):2196-9
pubmed: 23558524
Blood. 2009 Oct 22;114(17):3615-24
pubmed: 19690339
Blood. 2009 Jan 8;113(2):403-11
pubmed: 18948572
Blood. 2012 Mar 1;119(9):2106-9
pubmed: 22234701
Clin Cancer Res. 2012 Apr 1;18(7):1870-8
pubmed: 22322667
Haematologica. 2018 Apr;103(4):e158-e161
pubmed: 29269523
Methods Mol Biol. 2019;1956:139-155
pubmed: 30779034
Lancet Haematol. 2017 Mar;4(3):e114-e126
pubmed: 28257752
Leukemia. 2017 Jul;31(7):1477-1481
pubmed: 28439111
Mol Med. 2012 Dec 06;18:1281-91
pubmed: 22437326
Blood. 2005 Nov 15;106(10):3575-83
pubmed: 16076869
Clin Cancer Res. 2018 Oct 15;24(20):5048-5057
pubmed: 29945996
Haematologica. 2016 Sep;101(9):e369-73
pubmed: 27479817
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Philos Trans R Soc Lond B Biol Sci. 2015 Sep 5;370(1676):
pubmed: 26194752
Haematologica. 2021 Apr 01;106(4):1178-1181
pubmed: 32586905
Blood. 1990 Aug 1;76(3):562-9
pubmed: 2378986
Leuk Lymphoma. 2015;56(11):3150-8
pubmed: 25860243
Br J Haematol. 2020 Jun;189(5):809-810
pubmed: 32002980
Mol Med. 2013 May 20;19:115-23
pubmed: 23615967
Clin Cancer Res. 2017 Sep 1;23(17):5292-5301
pubmed: 28536306
Haematologica. 2019 Dec 26;105(11):2598-2607
pubmed: 33131249
JCI Insight. 2017 Sep 7;2(17):
pubmed: 28878138
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
Leukemia. 2019 Feb;33(2):287-298
pubmed: 30555163
Leukemia. 2017 Feb;31(2):282-291
pubmed: 27811850
Cell. 2015 May 21;161(5):1026-1034
pubmed: 25959776
Semin Hematol. 2014 Jul;51(3):158-67
pubmed: 25048780
J Immunol. 2019 Dec 15;203(12):3095-3104
pubmed: 31818922
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Science. 2011 Sep 16;333(6049):1593-602
pubmed: 21835983
Haematologica. 2016 Aug;101(8):959-67
pubmed: 27198719
Semin Cancer Biol. 2015 Oct;34:22-35
pubmed: 25963298
Nat Commun. 2017 Jun 09;8:15746
pubmed: 28598442
Blood. 2015 Jun 4;125(23):3580-7
pubmed: 25900981
Br J Haematol. 2009 Feb;144(4):492-506
pubmed: 19036101
Blood. 2012 May 10;119(19):4467-75
pubmed: 22415752
Int J Cancer. 2019 Jun 1;144(11):2695-2706
pubmed: 30447004
Methods Mol Biol. 2012;882:569-604
pubmed: 22665256
BMC Bioinformatics. 2018 Nov 20;19(Suppl 14):414
pubmed: 30453883
Blood. 2010 Jan 7;115(1):71-7
pubmed: 19887677
Leukemia. 2012 Jul;26(7):1638-46
pubmed: 22222599
Cell. 2016 Jul 28;166(3):609-623
pubmed: 27453470
Leukemia. 2010 Jan;24(1):125-32
pubmed: 19759557
Haematologica. 2010 Dec;95(12):2072-9
pubmed: 20801898
Blood. 2018 May 24;131(21):2283-2296
pubmed: 29666114
Blood. 2015 Jan 29;125(5):856-9
pubmed: 25634617
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
Blood. 2008 Dec 15;112(13):5122-9
pubmed: 18812466
Leukemia. 2010 Jul;24(7):1317-24
pubmed: 20463750
Br J Haematol. 2014 Aug;166(4):621-5
pubmed: 24725250
Clin Cancer Res. 2009 Jul 1;15(13):4415-22
pubmed: 19509140
Am J Hematol. 2014 Jan;89(1):74-82
pubmed: 24030933
Leukemia. 2018 Jan;32(1):83-91
pubmed: 28592889
Blood Adv. 2020 Apr 14;4(7):1357-1366
pubmed: 32267931
Blood. 2011 Sep 15;118(11):3088-95
pubmed: 21791422
Mol Med. 2020 Mar 10;26(1):25
pubmed: 32156260
Epigenetics. 2012 Dec 1;7(12):1435-42
pubmed: 23154584
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4320-4327
pubmed: 32047037
Leukemia. 2019 Jul;33(7):1801-1805
pubmed: 30679797
Haematologica. 2011 Nov;96(11):1644-52
pubmed: 21750087
Immunity. 2013 Aug 22;39(2):245-58
pubmed: 23911655
Mol Med. 2017 Mar;23:1-12
pubmed: 28097289
Blood. 2015 Apr 16;125(16):2497-506
pubmed: 25700432
Immunity. 2014 Dec 18;41(6):909-18
pubmed: 25526306
Immunity. 2000 Jul;13(1):37-45
pubmed: 10933393
J Clin Invest. 1998 Oct 15;102(8):1515-25
pubmed: 9788964
PLoS One. 2011;6(8):e24313
pubmed: 21897877
Haematologica. 2019 Feb;104(2):360-369
pubmed: 30262567
Blood. 2008 Feb 1;111(3):1524-33
pubmed: 17959859
J Clin Invest. 2005 Jun;115(6):1636-43
pubmed: 15902303
J Immunol. 2016 May 15;196(10):4410-7
pubmed: 27059597
Blood. 2010 May 13;115(19):3907-15
pubmed: 20110421
Lancet Haematol. 2014 Nov;1(2):e74-84
pubmed: 27030157
Blood. 2007 Jan 1;109(1):259-70
pubmed: 16985177
Blood. 1999 Sep 15;94(6):1848-54
pubmed: 10477713

Auteurs

Andreas Agathangelidis (A)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Anastasia Chatzidimitriou (A)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.

Katerina Gemenetzi (K)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.

Veronique Giudicelli (V)

International ImMunoGeneTics Information System (IMGT), Laboratoire d'ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH), Unité Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), Université de Montpellier, Montpellier, France.

Maria Karypidou (M)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Karla Plevova (K)

Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.
Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Zadie Davis (Z)

Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.

Xiao-Jie Yan (XJ)

The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY.

Sabine Jeromin (S)

MLL Munich Leukemia Laboratory, Munich, Germany.

Christof Schneider (C)

University Hospital Medical Center, Ulm, Germany.

Lone Bredo Pedersen (LB)

Deparment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Renee C Tschumper (RC)

Department of Immunology, Mayo Clinic, Rochester, MN.

Lesley-Ann Sutton (LA)

Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.

Panagiotis Baliakas (P)

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Lydia Scarfò (L)

Strategic Research Program on CLL, B-Cell Neoplasia Unit, Division of Experimental Oncology, Università Vita-Salute San Raffaele/Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.

Ellen J van Gastel (EJ)

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center (UMC), Rotterdam, The Netherlands.

Marine Armand (M)

Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne Université, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

Eugen Tausch (E)

Department of Internal Medicine III, Ulm University, Ulm, Germany.

Bella Biderman (B)

National Research Center for Hematology, Moscow, Russia.

Constance Baer (C)

MLL Munich Leukemia Laboratory, Munich, Germany.

Davide Bagnara (D)

Department of Experimental Medicine, University of Genoa, Genoa, Italy.

Alba Navarro (A)

Centro de Investigacion Biomedica en Red en Oncologia (CIBERONC), Madrid, Spain.
Institut d'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain.

Anne Langlois de Septenville (A)

Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne Université, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

Valentina Guido (V)

Molecular Pathology Unit, Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.

Gerlinde Mitterbauer-Hohendanner (G)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Aleksandar Dimovski (A)

Faculty of Pharmacy, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Northern Macedonia.

Christian Brieghel (C)

Deparment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Sarah Lawless (S)

Clinical Haematology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom.

Manja Meggendorfer (M)

MLL Munich Leukemia Laboratory, Munich, Germany.

Kamila Brazdilova (K)

Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.
Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Matthias Ritgen (M)

Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Monica Facco (M)

Hematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Veneto Institute of Molecular Medicine, Padua, Italy.

Cristina Tresoldi (C)

Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Andrea Visentin (A)

Hematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Veneto Institute of Molecular Medicine, Padua, Italy.

Andrea Patriarca (A)

Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont-Ospedale Maggiore della Carità, Novara, Italy.

Mark Catherwood (M)

Clinical Haematology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom.

Lisa Bonello (L)

General Anatomopathology and Molecular Oncogenetics, Azienda Ospedaliero Universitaria (AOU), City of Health and Science of Turin, Turin, Italy.

Andrey Sudarikov (A)

National Research Center for Hematology, Moscow, Russia.

Katrina Vanura (K)

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Maria Roumelioti (M)

First Department of Propaedeutic Medicine, University of Athens, Athens, Greece.

Hana Skuhrova Francova (H)

Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.

Theodoros Moysiadis (T)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Silvio Veronese (S)

Molecular Pathology Unit, Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.

Krzysztof Giannopoulos (K)

Experimental Hematooncology Department, Medical University of Lublin, Lublin, Poland.

Larry Mansouri (L)

Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.

Teodora Karan-Djurasevic (T)

Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.

Raphael Sandaltzopoulos (R)

Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.

Csaba Bödör (C)

MTA-SE Momentum Molecular Oncohematology Research Group, First Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Franco Fais (F)

Department of Experimental Medicine, University of Genoa, Genoa, Italy.
UO Molecular Pathology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Arnon P Kater (AP)

Department of Hematology, Amsterdam Infection and Immunity Institute, Cancer Center Amsterdam, Amsterdam UMC-University of Amsterdam, Amsterdam, The Netherlands.

Irina Panovska (I)

Department of Hematology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Northern Macedonia.

Davide Rossi (D)

Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

Salem Alshemmari (S)

Department of Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait.

Panagiotis Panagiotidis (P)

First Department of Propaedeutic Medicine, University of Athens, Athens, Greece.

Paul Costeas (P)

The Center for the Study of Haematological Malignancies, Nicosia, Cyprus.
Karaiskakio Foundation, Nicosia, Cyprus.

Blanca Espinet (B)

Laboratorio de Citogenètica Molecular, Laboratori de Citologia Hematològica, Servei de Patologia i Servei de Hematologia, Hospital del Mar, Barcelona, Spain.

Darko Antic (D)

Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia.

Letizia Foroni (L)

Hammersmith Hospital, London, United Kingdom.

Marco Montillo (M)

Molecular Pathology Unit, Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.

Livio Trentin (L)

Hematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Veneto Institute of Molecular Medicine, Padua, Italy.

Niki Stavroyianni (N)

Hematocrit (HCT) Unit, Hematology Department, G. Papanicolaou Hospital, Thessaloniki, Greece.

Gianluca Gaidano (G)

Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont-Ospedale Maggiore della Carità, Novara, Italy.

Paola Francia di Celle (P)

General Anatomopathology and Molecular Oncogenetics, Azienda Ospedaliero Universitaria (AOU), City of Health and Science of Turin, Turin, Italy.

Carsten Niemann (C)

Deparment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Elias Campo (E)

Centro de Investigacion Biomedica en Red en Oncologia (CIBERONC), Madrid, Spain.
Institut d'Investigacions Biomediques August Pi I Sunyer, Barcelona, Spain.
Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.

Achilles Anagnostopoulos (A)

Hammersmith Hospital, London, United Kingdom.

Christiane Pott (C)

Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Kirsten Fischer (K)

University Hospital Cologne, Cologne, Germany.

Michael Hallek (M)

Department I of Internal Medicine, University of Cologne, Cologne, Germany.

David Oscier (D)

Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.

Stephan Stilgenbauer (S)

Department of Internal Medicine III, Ulm University, Ulm, Germany.

Claudia Haferlach (C)

MLL Munich Leukemia Laboratory, Munich, Germany.

Diane Jelinek (D)

Department of Immunology, Mayo Clinic, Scottsdale, AZ.

Nicholas Chiorazzi (N)

The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY.

Sarka Pospisilova (S)

Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.
Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Marie-Paule Lefranc (MP)

International ImMunoGeneTics Information System (IMGT), Laboratoire d'ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH), Unité Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), Université de Montpellier, Montpellier, France.

Sofia Kossida (S)

International ImMunoGeneTics Information System (IMGT), Laboratoire d'ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH), Unité Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), Université de Montpellier, Montpellier, France.

Anton W Langerak (AW)

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center (UMC), Rotterdam, The Netherlands.

Chrysoula Belessi (C)

Hematology Department, Nikea General Hospital, Pireaus, Greece; and.

Frederic Davi (F)

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center (UMC), Rotterdam, The Netherlands.

Richard Rosenquist (R)

Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Clinical Genetics, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.

Paolo Ghia (P)

Strategic Research Program on CLL, B-Cell Neoplasia Unit, Division of Experimental Oncology, Università Vita-Salute San Raffaele/Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.

Kostas Stamatopoulos (K)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH